You are here: Industry Insights > Sorrento

News List

Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of C firstwordpharma
August 20, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain .
Sorrento gets Brazilian ANVISA’s clearance for Phase II Covid-19 trial pharmaceutical-technology
May 24, 2021
Sorrento Therapeutics has received clearance from the Brazilian regulatory agency ANVISA to conduct a Phase II clinical trial of an injectable infusion of mesenchymal stem cells, COVI-MSC, to treat Covid-19 patients with acute respiratory distress ...
Sorrento gets US FDA nod for Phase 1 clinical trial of neutralising antibody in COVID-19 patients expresspharma
September 18, 2020
Sorrento had earlier informed that COVI-GUARD (STI-1499) demonstrated 100 per cent in vitro neutralizing effect against SARS-CoV-2.
Sorrento to merge with gene-encoded therapies firm SmartPharm pharmaceutical-technology
August 24, 2020
Sorrento Therapeutics has entered into a merger agreement to acquire gene-encoded therapeutics firm SmartPharm for an aggregate of up to $19.4m shares of Sorrento common stock.
FDA Clears Abivertinib for Safety, Efficacy Study in COVID-19 Hospitalized Patients americanpharmaceuticalreview
July 28, 2020
Sorrento Therapeutics received clearance from the FDA to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms.
Sorrento to Acquire SmartPharm contractpharma
July 27, 2020
Gains non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.
Sorrento, Mount Sinai to Develop COVI-Shield Antibody Therapy contractpharma
May 13, 2020
Sorrento Therapeutics Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-Shield) to potentially treat COVID-19.
Sorrento and Mount Sinai to develop antibody cocktail against Covid-19 pharmaceutical-technology
May 12, 2020
Sorrento Therapeutics has collaborated with Mount Sinai Health System to develop an antibody cocktail, COVI-SHIELD, for the potential treatment of Covid-19.